Results 71 to 80 of about 231,116 (154)

Supplementary Figures S1 - S9 from Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

, 2016
Supplementary Figure S1. Neoadjuvant immunotherapy is more effective at reducing metastatic burden. Supplementary Figure S2. Late neoadjuvant Treg depletion is more effective than adjuvant Treg depletion in eradicating metastatic disease.
Mark J. Smyth (42440), Stacey Allen (13580419), Michelle C.R. Yong (14914473), Shin Foong Ngiow (14898944), Michele W.L. Teng (14881461), Heidi Harjunpää (6740744), Kazuyoshi Takeda (3940), Jake S. O'Donnell (15022955), Jing Liu (38537), Arabella Young (313392), Stephen J. Blake (14924802)   +10 more
core   +1 more source

Research progress of neoadjuvant immunotherapy for non-small cell lung cancer and the challenge of evaluating therapeutic response with imaging methods

肿瘤影像学, 2022
Although surgical resection is the mainstay of treatment for patients with early stage and locally advanced stage of non-small cell lung cancer (NSCLC), distant and local recurrence occur relatively frequently, justifying the need for systemic therapy ...
LIU Ying, ZHANG Yuwei, YE Zhaoxiang
doaj  

Research progress of immune checkpoint inhibitors in neoadjuvant immunotherapy for dMMR/MSI-H locally advanced colorectal cancer

结直肠肛门外科
In recent years, immune checkpoint inhibitors (ICIs) have made great progress in the treatment of colorectal cancer, particularly in the post-line and first-line treatment of dMMR/MSH-H metastatic colorectal cancer patients, demonstrating good clinical ...
Zhu Xi, Li Yang, Jiang Jun, Li Guoli, Kao Xiaoming   +4 more
doaj   +1 more source

In‐Depth Analysis of the Necessity and Optimization Strategies for Adjuvant Radiotherapy Following Neoadjuvant Immunotherapy in the New Era of Esophageal Cancer Treatment

Cancer Innovation
As immunotherapy rises to prominence in cancer treatment, the therapeutic approach to esophageal cancer is undergoing significant transformations. This review emphasizes the necessity and optimization pathways for adjuvant postoperative radiotherapy ...
Guohui Liu, Yao Su, Yunlong He, Hanqing Hu   +3 more
doaj   +1 more source

Introducing Neoadjuvant Immunotherapy for Colorectal Cancer:Advancing the Frontier

Objective: To give surgeons a review of the current and future use of neoadjuvant immunotherapy in patients with localized colorectal cancer.Background: Immunotherapy has revolutionized the standard of care in oncology and improved survival outcomes in ...
Raskov, Hans, Orhan, Adile, Justesen, Tobias F., Qvortrup, Camilla, Gögenur, Ismail   +4 more
core   +1 more source

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy

, 2018
New clinical trials are now evaluating the efficacy of neoadjuvant immunotherapy in the context of primary tumor surgery. Using the orthotopic 4T1.2 mouse model of spontaneously metastatic mammary cancer, we have shown that neoadjuvant immunotherapy and ...
Liu, Jing, O’Donnell, Jake S., Teng, Michele W. L., Allen, Stacey, Rozeman, Elisa A., Smyth, Mark J., Fanchi, Lorenzo, Blank, Christian U.   +7 more
core   +1 more source

Tumor microenvironment(TME) and single-source dual-energy CT(ssDECT) on assessment of inconformity between RECIST1.1 and pathological remission in neoadjuvant immunotherapy of NSCLC

Neoplasia: An International Journal for Oncology Research
Background: The inconformity (IC) between pathological and imaging remissions after neoadjuvant immunotherapy in patients with NSCLC can affect the evaluation of curative effect of neoadjuvant therapy and the decision regarding the chance of surgery ...
Chao Sun, Xiaobo Ma, Fanyang Meng, Xi Chen, Xu Wang, Wenyu Sun, Yinghui Xu, Hua He, Huimao Zhang, Kewei Ma   +9 more
doaj   +1 more source

Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD)

BMC Cancer
Background Emerging data suggested a favorable outcome in advanced non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD) patients treated by immunotherapy. The objective of this study was to investigate the effectiveness of
Ao Zeng, Yanze Yin, Zhilong Xu, Abudumijiti Abuduwayiti, Fujun Yang, Mohammed Saud Shaik, Chao Wang, Keyi Chen, Chao Wang, Xinyun Fang, Jie Dai   +10 more
doaj   +1 more source

Current role of immunotherapy in gastrointestinal cancers

, 2023
Immunotherapy has emerged as a groundbreaking treatment modality in the field of oncology, revolutionizing the management of various cancer types, including gastrointestinal cancers.
Ampah, Richard Kobina
core  

Neoadjuvant immunotherapy for resectable non-small-cell lung cancer

Lung cancer is the commonest cause of cancer death worldwide and approximately 85% of cases are non-small-cell cancer (NSCLC). In the decade from 2010 to 2020 there were many new systemic therapies developed and approved for the treatment of advanced ...
Patrick Forde (6323729)
core   +1 more source